AAAAAA
Results:
1-8
|
Results: 8
Authors:
Twelves, C
Boyer, M
Findlay, M
Cassidy, J
Weitzel, C
Baker, C
Osterwalder, B
Jamieson, C
Hieke, K
Citation: C. Twelves et al., Capecitabine (Xeloda (TM)) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients withadvanced colorectal carcinoma, EUR J CANC, 37(5), 2001, pp. 597-604
Authors:
O'Shaughnessy, JA
Blum, J
Moiseyenko, V
Jones, SE
Miles, D
Bell, D
Rosso, R
Mauriac, L
Osterwalder, B
Burger, HU
Laws, S
Citation: Ja. O'Shaughnessy et al., Randomized, open-label, phase II trial of oral capecitabine (Xeloda((R))) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer, ANN ONCOL, 12(9), 2001, pp. 1247-1254
Authors:
Hoff, PM
Ansari, R
Batist, G
Cox, J
Kocha, W
Kuperminc, M
Maroun, J
Walde, D
Weaver, C
Harrison, E
Burger, HU
Osterwalder, B
Wang, AO
Wong, R
Citation: Pm. Hoff et al., Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study, J CL ONCOL, 19(8), 2001, pp. 2282-2292
Authors:
Van Cutsem, E
Twelves, C
Cassidy, J
Allman, D
Bajetta, E
Boyer, M
Bugat, R
Findlay, M
Frings, S
Jahn, M
McKendrick, J
Osterwalder, B
Perez-Manga, G
Rosso, R
Rougier, P
Schmiegel, WH
Seitz, JF
Thompson, P
Vieitez, JM
Weitzel, C
Harper, P
Citation: E. Van Cutsem et al., Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study, J CL ONCOL, 19(21), 2001, pp. 4097-4106
Authors:
Blum, JL
Dieras, V
Lo Russo, PM
Horton, J
Rutman, O
Buzdar, A
Osterwalder, B
Citation: Jl. Blum et al., Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients, CANCER, 92(7), 2001, pp. 1759-1768
Authors:
Van Cutsem, E
Findlay, M
Osterwalder, B
Kocha, W
Dalley, D
Pazdur, R
Cassidy, J
Dirix, L
Twelves, C
Allman, D
Seitz, JF
Scholmerich, J
Burger, HU
Verweij, J
Citation: E. Van Cutsem et al., Capecitabine, an oral fluoropyrimidine carbamate with substantial activityin advanced colorectal cancer: Results of a randomized phase II study, J CL ONCOL, 18(6), 2000, pp. 1337-1345
Authors:
Pronk, LC
Vasey, P
Sparreboom, A
Reigner, B
Planting, AST
Gordon, RJ
Osterwalder, B
Verweij, J
Twelves, C
Citation: Lc. Pronk et al., A phase I and pharmacokinetic study of the combination of capecitabine anddocetaxel in patients with advanced solid tumours, BR J CANC, 83(1), 2000, pp. 22-29
Authors:
Blum, JL
Jones, SE
Buzdar, AU
LoRusso, PM
Kuter, I
Vogel, C
Osterwalder, B
Burger, HU
Brown, CS
Griffin, T
Citation: Jl. Blum et al., Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer, J CL ONCOL, 17(2), 1999, pp. 485-493
Risultati:
1-8
|